دورية أكاديمية
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
| العنوان: | Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. |
|---|---|
| المؤلفون: | Kakuda TN; Janssen Research & Development, LLC, Titusville, NJ, USA tkakuda@its.jnj.com., Brochot A; Janssen Research and Development, BV, Beerse, Belgium., Tomaka FL; Janssen Research & Development, LLC, Titusville, NJ, USA., Vangeneugden T; Janssen Research and Development, BV, Beerse, Belgium., Van De Casteele T; Janssen Research and Development, BV, Beerse, Belgium., Hoetelmans RM; Janssen Research and Development, BV, Beerse, Belgium. |
| المصدر: | The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2014 Oct; Vol. 69 (10), pp. 2591-605. Date of Electronic Publication: 2014 Jun 20. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1997- : London : Oxford University Press Original Publication: London, New York, Academic Press. |
| مواضيع طبية MeSH: | HIV Infections/*drug therapy , HIV Protease Inhibitors/*administration & dosage , HIV Protease Inhibitors/*pharmacokinetics , Sulfonamides/*administration & dosage , Sulfonamides/*pharmacokinetics, Age Factors ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/pharmacokinetics ; Darunavir ; Drug Interactions ; Drug Therapy, Combination ; Female ; HIV Protease Inhibitors/adverse effects ; HIV-1 ; Humans ; Male ; Pregnancy ; Sex Factors ; Sulfonamides/adverse effects |
| مستخلص: | The ability to dose antiretroviral agents once daily simplifies the often complex therapeutic regimens required for the successful treatment of HIV infection. Thus, once-daily dosing can lead to improved patient adherence to medication and, consequently, sustained virological suppression and reduction in the risk of emergence of drug resistance. Several trials have evaluated once-daily darunavir/ritonavir in combination with other antiretrovirals (ARTEMIS and ODIN trials) or as monotherapy (MONET, MONOI and PROTEA trials) in HIV-1-infected adults. Data from ARTEMIS and ODIN demonstrate non-inferiority of once-daily darunavir/ritonavir against a comparator and, together with pharmacokinetic data, have established the suitability of once-daily darunavir/ritonavir for treatment-naive and treatment-experienced patients with no darunavir resistance-associated mutations. The findings of ARTEMIS and ODIN have led to recent updates to treatment guidelines, whereby once-daily darunavir/ritonavir, given with other antiretrovirals, is now a preferred treatment option for antiretroviral-naive adult patients and a simplified treatment option for antiretroviral-experienced adults who have no darunavir resistance-associated mutations. Once-daily dosing with darunavir/ritonavir is an option for treatment-naive and for treatment-experienced paediatric patients with no darunavir resistance-associated mutations based on the findings of the DIONE trial and ARIEL substudy. This article reviews the pharmacokinetics, efficacy, safety and tolerability of once-daily boosted darunavir. The feasibility of darunavir/ritonavir monotherapy as a treatment approach for some patients is also discussed. Finally, data on a fixed-dose combination of 800/150 mg of darunavir/cobicistat once daily are presented, showing comparable darunavir bioavailability to that obtained with 800/100 mg of darunavir/ritonavir once daily. (© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: HIV protease inhibitors; antiretroviral; pharmacology |
| المشرفين على المادة: | 0 (Anti-HIV Agents) 0 (HIV Protease Inhibitors) 0 (Sulfonamides) YO603Y8113 (Darunavir) |
| تواريخ الأحداث: | Date Created: 20140622 Date Completed: 20150528 Latest Revision: 20151119 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1093/jac/dku193 |
| PMID: | 24951533 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2091 |
|---|---|
| DOI: | 10.1093/jac/dku193 |